PRESS RELEASE

THE BOARD OF DIRECTORS OF SVAS BIOSANA

APPROVES THE CONSOLIDATED HALF-YEARLY FINANCIAL REPORT AS AT 30 JUNE 2022

RECORD GROWTH IN CONSOLIDATED REVENUES EUR 43.8 BILLION (+13.6% YoY)

GROWTH OF ALL BUSINESS LINES

  • Consolidated EBITDA: 5.7 million Euro (EBITDA Margin 13%).
  • Consolidated EBIT: 3.1 million Euro; EBIT Margin 7.1%.
  • Consolidated Net Income: 1.72 million Euro.
  • Group Net Financial Position (NFP) cash negative by Euro 25.3 million.
  • Bormia d.o.o., a company acquired in June 2022 with effect from 1 July 2022, generated a turnover of Euro 6.5 mln.

Somma Vesuviana (Naples Province) 26 September 2022 - Svas Biosana S.p.A. (the "Company" or "SVAS"), a leading operator in the healthcare sector, active in the production and distribution of medical devices for public and private healthcare facilities, listed on Euronext Growth Milan, announces that the Board of Directors, which met today, approved the consolidated half-yearlyreport as at 30 June 2022, subject to voluntary limited audit.

Umberto Perillo, CEO of Svas Biosana, has commented thus: "We are very pleased with the results for the first half-year,which show record growth in turnover compared to every previous year, in a trend that continues to grow. The substantial increase in inflation impacted profitability margins, while it had a marginal effect on device marketing activities. The results confirm the solid foundation and clear strategic vision of the Group and a successful business model. Thanks also to the listing, we are pursuing our growth project by adapting it to the particularly volatile economic and geopolitical environment. We are therefore pleased that our commitment and determination has been reflected in the figures presented, which we are happy to share with the market and our shareholders".

ANALYSIS OF KEY ECONOMIC AND FINANCIAL DATA

Despite the general context conditioned by the effects of the Russia-Ukraine conflict, the period ended 30 June 2022 was very positive for the Svas Biosana Group, especially in terms of consolidated revenues. The general increase in the cost of raw materials and energy - which had an impact on the cost structure of the Group's manufacturing activities - forced a revision of sales policies, in particular through two guidelines: a) a general increase in prices charged to customers, b) a greater focus on devices characterised by higher added value. This made it possible to mitigate the negative effect of inflation on the main factors of production.

Revenues from operations as at 30 June 2022 amounted to Euro 43.8 million, an increase of +13.6% compared to Euro 38.6 million as at 30 June 2021.

SVAS BIOSANA S.p.A.

Head Office

Correspondence

Headquarters and

Contacts

Offices

Companies Register of

Via M. Perillo, 34

Post Box 91

Via Trentola, 7

Tel. +390818995411

Naples no. 4543/85

80047

80049

80049

Fax +390818993922

R.E.A. No. 393065

San Giuseppe Vesuviano (NA)

Somma Vesuviana (NA)

Somma Vesuviana (NA)

www.svas.it

Tax code 04720630633

Italy

Italy

Italy

svasbiosana@legalmail.it

VAT no. 01354901215

The strong growth was driven by all business lines, as shown in the table below, with double digit growth.

Business Unit

Turnover

% of

Turnover

% of

1H/22 vs 1H/21

1H/2022

total

1H/2021

total

SVAS

10.0

22.4%

9.0

23.1%

11.0%

FARMEX

14.0

31.4%

13.2

33.9%

6.2%

MEDICAL

4.5

10.2%

3.9

10.1%

15.3%

MARK MEDICAL

16.0

36.0%

12.8

32.9%

25.0%

CONSOLIDATED REVENUES

44.6

100%

38.9

100%

14.4%

Intra-group revenues

-0.7

-0.3

TOTAL CONSOLIDATED REVENUE

43.8

38.6

13.6%

These figures do not include the pro-forma Revenues of the Bormia Group, a leading supplier of medical devices in the Balkan region, which was acquired on 23 June 2022, effective 1 July 2022, and which reported revenues of approximately EUR 6.5 million in the first half of 2022.

Geographically, 64 % of revenues were generated in Italy (66 % in 2021) and 36 % abroad (34 % in 2021), confirming the Group's good international vocation.

Value of Production amounted to Euro 46.1 million, compared to Euro 39.3 million in H1 2021 (17.2% YoY ).

EBITDA(Gross Operating Margin) amounted to Euro 5.7 million, substantially in line with the same period of 2021 due to the increase in raw material costs, which absorbed the positive effect of the increase in revenue. The EBITDA margin is 13.0% on revenue.

EBIT (Operating Profit) amounted to Euro 3.1 million, down 9.4% (compared to Euro 3.4 million as at 30 June 2021) with an EBIT margin of 7.1% on revenue, while Net Profit was positive at Euro 1.72 million (compared to Euro 1.97 million in 2021).

The Net Financial Position was cash negative for Euro 25.3 million, compared to the cash negative NFP of Euro 17.0 million as of 31 December 2021, mainly due to the acquisition of the Bormia d.o.o. Group for Euro

4.8 million and a higher absorption of working capital attributable to the volatility experienced in the supply chain.

Shareholders' Equity amounted to Euro 52.7 million compared to Euro 51 million as at 31 December 2021. The increase is attributable to the profit for the year 2021 being allocated to reserves.

SVAS BIOSANA S.p.A.

Head Office

Correspondence

Headquarters and

Contacts

Offices

Companies Register of

Via M. Perillo, 34

Post Box 91

Via Trentola, 7

Tel. +390818995411

Naples no. 4543/85

80047

80049

80049

Fax +390818993922

R.E.A. No. 393065

San Giuseppe Vesuviano (NA)

Somma Vesuviana (NA)

Somma Vesuviana (NA)

www.svas.it

Tax code 04720630633

Italy

Italy

Italy

svasbiosana@legalmail.it

VAT no. 01354901215

SIGNIFICANT EVENTS DURING THE FIRST HALF OF THE YEAR

  • On 7 January 2021, Banca Profilo S.p.A. and Illimity Bank S.p.A., as Joint Global Coordinator, fully exercised the Greenshoe option granted by Agrinvest S.r.l. for the purchase of 240,000 Shares, amounting to 15% of the number of Shares object of the Private Placement.
  • On 23 June 2022, there was the closing of an acquisition concerning 75% of the share capital of the company Bormia d.o.o. ("Bormia"), which is active in the distribution of specialised medical devices to primary public and private customers in the Slovenian, Croatian, Serbian and Bosnian health care systems. The acquisition took place through Levante HC Holding, a wholly-owned subsidiary of Svas Biosana S.p.A., and was effective on 1 July 2022.

SIGNIFICANT EVENTS OCCURRING AFTER 30 JUNE 2022

No significant events were noted.

OUTLOOK

At the macroeconomic level, the outlook for economic activity and inflation has become highly uncertain and depends crucially on the evolution of the Russian-Ukrainian conflict, the impact of the sanctions currently in place and of possible further measures. It is hoped that the current disruptions in the supply of energy and raw materials and the negative effects on confidence related to the conflict will be temporary, and that there will be no significant impact on global supply chains.

The health emergency, resulting from the spread of the 'Covid-19' virus, continues to have an economic impact in 2022, albeit mitigated. At the moment, there are no particular criticalities to be reported, the characteristics of the variants in circulation and the massive vaccination campaign have greatly diminished the effects on economic activities and people's health. All economic activities have resumed their normal pace and expectations are very positive in general.

As things stand, however, the scenario is constantly and rapidly changing and it is not possible to predict the consequences that will be seen on the general scenario.

Under the current macroeconomic conditions, and if these do not change significantly, the company's management confirms the current positive trends, both with regard to sales and expected margins.

* * * * * * *

In accordance with the provisions of the Euronext Growth Milan Issuers' Regulations, the half-yearly report as at 30 June 2022 will be made available to the public, within the terms of the law, at the company's registered office, at Borsa Italiana S.p.A. and in the relevant sections of the website www.svas.itas of today, while the auditors' report will be available to the public on 28 September 2022 through the channels indicated above.

* * * * * * *

This press release can be found at Borsa Italiana, at the company's registered office, and in the Financial Releases section of the company's website www.svas.it.

SVAS BIOSANA S.p.A.

Head Office

Correspondence

Headquarters and

Contacts

Offices

Companies Register of

Via M. Perillo, 34

Post Box 91

Via Trentola, 7

Tel. +390818995411

Naples no. 4543/85

80047

80049

80049

Fax +390818993922

R.E.A. No. 393065

San Giuseppe Vesuviano (NA)

Somma Vesuviana (NA)

Somma Vesuviana (NA)

www.svas.it

Tax code 04720630633

Italy

Italy

Italy

svasbiosana@legalmail.it

VAT no. 01354901215

Svas Biosana uses the eMarket SDIR system, managed by Spafid Connect S.p.A., with registered office at Foro Buonaparte 10, Milan (www.emarketstorage.com), to disclose regulated information.

* * * * * * *

This press release may contain forward-looking statements about future events and results of the Svas Biosana Group that are based on current expectations, estimates and projections about the industry in which the Group operates and on management's current views. These elements inherently have a component of risk and uncertainty because they depend on the occurrence of future events and on a multiplicity of factors, many of which are beyond the company's control, including global macroeconomic conditions, changes in business conditions, further deterioration of markets, the impact of competition, political, economic and regulatory developments in Italy.

Contacts:

SVAS Biosana S.p.A.

Euronext Growth Advisor

Andrea Efficace

Banca Profilo

CFO Group and Investor Relations Manager

Milan, Via Cerva 128

+39 081.8995411

+39 02.584081

a.efficace@svas.it

alessio.muretti@bancaprofilo.it

Investor Relations Advisor

Media Relations Advisor

POLYTEMS HIR

POLYTEMS HIR

Bianca FERSINI MASTELLONI - Silvia MARONGIU

Paolo SANTAGOSTINO

06.69923324-066797849

+393493856585

s.marongiu@polytemshir.it

p.santagostino@polytemshir.it

Specialist

Banca Profilo

+39/02.584081

Svas Biosana manufactures and distributes medical devices in Italy and abroad. Founded in 1972 in Somma Vesuviana (NA) by the Perillo family, SVAS is now an international company with a catalogue of approximately 16,000 own and third party brand products, roughly 390 employees, a Research and Development department, three production facilities in Italy and subsidiaries in Slovenia, Croatia, Serbia and Bosnia- Herzegovina.

Ticker: ISIN Ordinary Shares: IT0005469264 Ticker: ISIN Warrant SVAS BIOSANA 2021-2024: IT0005469157

SVAS BIOSANA S.p.A.

Head Office

Correspondence

Headquarters and

Contacts

Offices

Companies Register of

Via M. Perillo, 34

Post Box 91

Via Trentola, 7

Tel. +390818995411

Naples no. 4543/85

80047

80049

80049

Fax +390818993922

R.E.A. No. 393065

San Giuseppe Vesuviano (NA)

Somma Vesuviana (NA)

Somma Vesuviana (NA)

www.svas.it

Tax code 04720630633

Italy

Italy

Italy

svasbiosana@legalmail.it

VAT no. 01354901215

CONSOLIDATED INCOME STATEMENT AS AT 30 JUNE 2022

30/06/2022

%

30/06/2021

%

Delta

Net revenues

43,843,886

100.0%

38,590,566

100.0%

13.6%

External costs

33,165,592

75.6%

27,710,174

71.8%

19.7%

Added value

10,678,294

24.4%

10,880,392

28.2%

(1,9%)

Cost of labour

5,822,602

13.3%

5,560,999

14.4%

4.7%

Other revenues

846,895

1.9%

422,188

1.1%

100.6%

Gross operating margin

5,702,587

13.0%

5,741,581

14.9%

(0,7%)

Amortisation, depreciation and

2,584,888

5.9%

2,299,351

6.0%

12.4%

other allocations

Operating result

3,117,699

7.1%

3,442,230

8.9%

(9,4%)

Financial income and costs

(818,456)

(1,9%)

(800,102)

-2.1%

2.3%

Ordinary result

2,299,243

5.2%

2,642,128

6.8%

(13,0%)

Revaluations and write-downs

-

-

0.0%

Pre-tax profit

2,299,243

5.2%

2,642,128

6.8%

(13,0%)

Income taxes

583,351

1.3%

668,023

1.7%

(12,7%)

Net income

1,715,892

3.9%

1,974,105

5.1%

(13,1%)

SVAS BIOSANA S.p.A.

Head Office

Correspondence

Headquarters and

Contacts

Offices

Companies Register of

Via M. Perillo, 34

Post Box 91

Via Trentola, 7

Tel. +390818995411

Naples no. 4543/85

80047

80049

80049

Fax +390818993922

R.E.A. No. 393065

San Giuseppe Vesuviano (NA)

Somma Vesuviana (NA)

Somma Vesuviana (NA)

www.svas.it

Tax code 04720630633

Italy

Italy

Italy

svasbiosana@legalmail.it

VAT no. 01354901215

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Svas Biosana S.p.A. published this content on 28 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 September 2022 10:35:01 UTC.